Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Greenwich LifeSciencesGLSI -4.83%34 Market Cap is $187.88 Mil as of Jul. 29, 2026. GuruFocus rates GLSI with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,421 Biotechnology companies, Greenwich LifeSciences ranks better than 58.9% on this metric.
Greenwich LifeSciences's quarterly market cap
increased
from Sep. 2025 ($137.26 Mil) to Dec. 2025 ($300.40 Mil) and
increased
from Dec. 2025 ($300.40 Mil) to Mar. 2026 ($352.28 Mil).
Greenwich LifeSciences's annual market cap
increased
from Dec. 2023 ($135.16 Mil) to Dec. 2024 ($147.71 Mil) and
increased
from Dec. 2024 ($147.71 Mil) to Dec. 2025 ($300.40 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Greenwich LifeSciences's Enterprise Value for Today is $177.38 Mil.
Greenwich LifeSciences (NAS:GLSI) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Greenwich LifeSciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Greenwich LifeSciences Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Greenwich LifeSciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Greenwich LifeSciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Greenwich LifeSciences's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Greenwich LifeSciences (GLSI) has a Market Cap of $187.88 Mil as of Jul. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Greenwich LifeSciences and its competitors. According to the industry distribution chart, Greenwich LifeSciences ranks #584 out of 1421 companies in the Biotechnology industry, placing it in the top 41.1%.
Is Greenwich LifeSciences' Market Cap too high?
Greenwich LifeSciences' current Market Cap is $187.88 Mil. The Biotechnology industry median Market Cap is 111.82. Greenwich LifeSciences' value of $187.88 Mil is 68% above this industry median. Based on the distribution chart, Greenwich LifeSciences ranks #584 out of 1421 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Greenwich LifeSciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Greenwich LifeSciences' Market Cap compare to PLX and DTIL?
According to the Biotechnology industry distribution chart, Greenwich LifeSciences ranks #584 out of 1421 companies for Market Cap. This puts Greenwich LifeSciences in the upper half of its industry. The industry median Market Cap is 111.82. Greenwich LifeSciences' value of $187.88 Mil is 68% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 111.82, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Greenwich LifeSciences's current Market Cap of $187.88 Mil is 68% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Greenwich LifeSciences and its competitors. For the Biotechnology industry, the median Market Cap is 111.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Greenwich LifeSciences's current Market Cap is $187.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greenwich LifeSciences stock overvalued right now?
Greenwich LifeSciences (GLSI) has a current Market Cap of $187.88 Mil. The current Market Cap is $187.88 Mil and 68% above the Biotechnology industry median of 111.82. Greenwich LifeSciences' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Greenwich LifeSciences (GLSI), the current Market Cap is $187.88 Mil as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
34GF Score
Get the complete analysis for GLSI
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLSI has been successfully added to your 
